On October 13, 2026, the day after the official event marking the clinical launch of GammaPod at the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples, experts and researchers from leading Italian and US oncology institutions gathered to explore new therapeutic perspectives and advance clinical research in breast cancer treatment.
The International GammaPod Clinical Consortium Meeting provided a forum for scientific exchange on the clinical applications of GammaPod, a dedicated stereotactic radiotherapy system specifically designed for precise, targeted treatment of breast cancer.
The meeting highlighted the importance of complementing technological innovation with rigorous clinical research to translate its potential into new therapeutic opportunities.
International Collaboration to Shape the Future of Breast Radiotherapy
The International GammaPod Clinical Consortium brings together leading institutions in oncology research, including the University of Maryland School of Medicine in Baltimore, UT Southwestern Medical Center in Dallas, and the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples.
The scientific sessions explored the potential of single-fraction stereotactic breast radiotherapy, with particular attention to emerging treatment approaches, including its use before surgery and its potential integration with innovative systemic therapies.
Discussions among specialists laid the groundwork for further scientific investigation and the development of collaborative research initiatives
Beyond Technological Innovation: Improving Patients' Quality Of Life
The clinical launch of GammaPod at the Pascale Institute is part of a broader international scientific collaboration aimed at exploring increasingly personalized and effective treatment strategies, with a strong focus on women's quality of life.
Because true innovation goes beyond treating disease. It is about empowering patients not just to survive but to thrive!
